Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 14/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 10/20 | 0.65 |
| ▸ | SRC | P12931 | 7/20 | 0.65 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102875 | 0.87 | AURKA (0.65) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL15722709 | 0.80 | AURKA (0.56) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL21000823 | 0.80 | AURKA (1.00) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL12430446 | 0.79 | AURKA (1.00) | AURKAAURKBGSK3BSRCAURKC | |
| SCHEMBL12430804 | 0.77 | AURKA (0.70) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL19990474 | 0.77 | AURKA (0.76) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL3967338 | 0.77 | AURKA (0.59) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL802286 | 0.77 | ITK (0.69) | AURKAAURKBGSK3BSRCITK | |
| SCHEMBL30353191 | 0.76 | AURKA (0.67) | AURKAAURKBNTRK1GSK3BSRC | |
| SCHEMBL22767705 | 0.76 | AURKA (0.67) | AURKAAURKBNTRK1GSK3BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140141099-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-05-22 | — | — | US | disclosed |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141099-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | AURKA 3/4885AURKB 1/4885NTRK1 1571/4885 |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | AURKA 3/4885AURKB 1/4885NTRK1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.